Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Bioretec Oy, a Finnish medical device company, specializes in the development and production of innovative biodegradable implants for orthopedic and pediatric surgery. The primary function of Bioretec Oy is to advance surgical outcomes through its patented bioabsorbable materials that assist in the healing process, reducing the need for follow-up surgeries often required with traditional metallic implants. This company focuses significantly on the healthcare and biotechnology sectors, predominantly impacting surgical practices and patient care standards. Bioretec Oy's implants are particularly notable for their biocompatibility and environmental sustainability, addressing both clinical needs and ecologically responsible practices. These implants dissolve naturally in the body, minimizing complications associated with long-term implant retention. In the financial market, Bioretec Oy represents a niche but crucial segment of the broader medical technology field, providing investors exposure to the evolving healthcare technologies sector. With its commitment to innovation, Bioretec Oy plays a pivotal role in enhancing patient recovery processes, thereby influencing trends in surgical methods and healthcare outcomes globally.
€0.02
+€0.00 (+1.92%)
EOD Jul 1, 2026
The business is unprofitable at the operating level (-246.64% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 22.5% YoY. Margins deteriorated 154.2pp alongside, both lines moving the wrong way.
ROIC dropped from -33.73% to -66.60%, capital efficiency is deteriorating. Negative free cash flow of -€10M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€4M
▼ -22.5% YoY
Net Income (TTM)
-€9M
▼ -105.5% YoY
Op. Margin
-246.64%
▼ -154.2pp YoY
ROIC
-66.60%
▼ -32.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€10M
▼ -77.3% YoY
Op. Cash Flow (TTM)
-€10M
▼ -97.0% YoY
Net Debt
-€4M
Net Cash Position
Cash & Equiv.
€4M
3Y CAGR: +6.2%
Continue Research
Bioretec Oy (BRETEC.XHEL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Bioretec Oy scores 21/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Bioretec Oy scores 21 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -246.6% operating margin and a -66.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh BRETEC.XHEL's valuation and scores 21/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.